This material is an English translation of the press release announced on Feb. 3, 2025 in Japanese, and the Japanese release is given priority about the content and the interpretation.

Feb. 3, 2025

Notification regarding Investment in ReEir, Inc., Bio-venture for Regenerative Medicine and Cell Medicine Development

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu City, Saga Prefecture; President and CEO:NAKATOMI, Kazuhide; hereinafter "Hisamitsu Pharmaceutical") has acquired a third-party allotment of new shares in ReEir, Inc. (Head Office: Minato-ku, Tokyo; Representative Director & President: TANAKA, Rica; hereinafter "ReEir"), a bio-venture company originating from Juntendo University, making a capital investment in the company.

ReEir is a bio-venture company engaged in developing of novel therapies for vascular and tissue regeneration, utilizing the research of Dr. Tanaka Rica, Professor and Chairman, Division of Regenerative Therapy at Juntendo University Graduate School of Medicine (Professor of plastic surgery courses). ReEir has the technology to quickly produce a cell population with high vascular regenerative, wound-healing and anti-inflammatory effects by drawing a small amount of blood, and aims to reduce the number of patients suffering from ischemic diseases, such as limb ischemic wounds through the development and commercialization of regenerative medicine and cell therapy that can be achieved simply from a small blood sample.

ReEir is expected to meet an unmet medical need, preventing a significant decline in QOL of patients as a result of severe pain, gangrene, and amputation caused by limb ischemia using minimally invasive treatment. With this capital investment, we hope to support the further growth of ReEir and to obtain new knowledge and to enhance our technological and human resource capabilities beyond the framework of our existing operations.

Hisamitsu Pharmaceutical will continue our business activities based on the technologies and expertise we have cultivated to date, while also creating new value by exploring other methodologies including partnering with other companies and M&A etc.

Company name	ReEir Inc.
Business details	Development of medical products such as regenerative medicine
Location	12F Garden Tower, 1-6-1 Roppongi, Minato-ku, Tokyo
Date of Establishment	September 2017
Representative	TANAKA, Rica, Representative Director & President
URL	https://www.re-eir.com/

[Overview of ReEir Inc.]